Drugs / Y90 Ibritumomab Tiuxetan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01446562 | May 2007 → May 2016 | follicular lymphoma | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y90 Ibritumomab Tiuxetan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01446562 ↗ |
| Modality | Other / unclassified | “radio- immunotherapy with 90-Yttrium ibritumomab tiuxetan consolidation” PMID 29709062 ↗ Apr 2018 |